The Global Landscape of Tuberculosis Therapeutics

Published Date:

01/31/2019

Source:

Annu Rev Med

Authors:

Tornheim JA, Dooley KE

External link

Original Article

Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

Events

«

November 2019

»
S
M
T
W
T
F
S
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Projects

Modeling to improve TB decision-making in the...

We are part of a large consortium that is constructing epidemic and economic models of TB and HIV in collaboration with the U.S....

Read More

Options for Patient-Centered Delivery of...

This individually randomized trial is evaluating the relative effectiveness of self-administered therapy, directly observed...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More

TB Modeling and Analysis Consortium

The TB MAC brings TB modelers together from a wide range of institutions to answer questions of global policy relevance.  I...

Read More